Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Crossflo revenue - how it will be presented. From last 10Q

Re: Moore's statement just days ago.."recently".. Considering

posted on Jun 02, 2009 02:26PM

I am not so much interested in individual license fees; I am interested in the MMP strategy, the response to the shareholders about issues and questions relevant to public information (i.e. USPTO), the response to highly questionable information floating in cyberspace regarding our most valuable asset and its overall ownership and management; and the notion that we have to read between the lines of news releases put forth by others (i.e. Alliacense) to get any idea of the current or potential revenue stream.

Its not about what Sanyo paid, it is about whether our BoD and our management believes the MMP is still worth in excess of $1 billion, and their strategy for maximizing and monetizing the value.




Share
New Message
Please login to post a reply